Last updated: 2026-09-16 12:18:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Immix Biopharma, Inc. (IMMX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $12.85, with a market capitalisation of $873.50M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.94 to $15.10. This page covers its latest market performance, valuation, price trends and company information.
$873.50M | |
$12.41 | |
$15.10 | |
$0.68 | |
$12.14 | |
-- | |
1.84M | |
-- | |
$15.10 | |
$1.94 | |
-- | |
-- |
Immix Biopharma, Inc. (IMMX) is trading at $12.85 in pre-market trading as of 2026-09-16 08:13:00, up 5.84% ($0.71) from the previous close of $12.14
Pre-market trading shows how investors are pricing IMMX before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Immix Biopharma, Inc. (IMMX) moved from $13.91 to $12.85, representing a decline of 7.63% ($1.06).
The stock traded between $11.81 and $14.09 during the period. The latest price is near the middle of the 7-day range, indicating strong downward.
The average daily volume was 1.25 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 82.9%
IMMX is currently trading at $12.85, placing it 82.9% of the way from its 52-week low of $1.94 to its 52-week high of $15.10. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 21 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Immix Biopharma, Inc. (IMMX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.